arginyl-glycyl-aspartic acid has been researched along with Bright Disease in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Amann, K; Daniel, C; Haas, CS; Hartner, A; Schöcklmann, HO; Schüssler, J | 1 |
Fischer, EG | 1 |
2 other study(ies) available for arginyl-glycyl-aspartic acid and Bright Disease
Article | Year |
---|---|
Beneficial effects of integrin αvβ3-blocking RGD peptides in early but not late phase of experimental glomerulonephritis.
Topics: Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Creatinine; Crotalid Venoms; Disease Models, Animal; Dose-Response Relationship, Drug; Glomerulonephritis; In Vitro Techniques; Integrin alphaVbeta3; Male; Mesangial Cells; Mice; Mice, Inbred C57BL; Oligopeptides; Time Factors | 2012 |
Glomerular mesangial cell adhesion to fibrinogen is mediated by alphavbeta3 integrin.
Topics: Animals; Cell Adhesion; Cells, Cultured; Extracellular Matrix Proteins; Fibrinogen; Glomerular Mesangium; Glomerulonephritis; Integrin alphaVbeta3; Oligopeptides; Protein Binding; Rats | 2004 |